A new 'seek-and-destroy' gene therapeutic system could have the potential to treat prostate cancer in the future, after it halted the majority of tumors in laboratory models at the University of Strathclyde and the Beatson Institute.
The system was used against two types of prostate tumor, causing 70% of one type and 50% of the other to vanish over a period of one month.These results are a promising start for the system as it continues its progress towards the clinic.
Prostate cancer is the fourth most widespread cancer in the world, the second most common in men and the most commonplace in Europe and North America. It causes the death of 300,000 patients worldwide each year and its incidence has continually increased over the last two decades.
The research has been published in the journal Drug Delivery. It involved researchers from Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde's Department of Pure and Applied Chemistry and the Cancer Research UK Beatson Institute in Glasgow.
Dr Christine Dufès, a Senior Lecturer in Strathclyde Institute of Pharmacy and Biomedical Sciences, led the research. She said: "Although some treatments, including chemotherapy and radiotherapy, can be effective against localized tumors, there is still no effective treatment for patients whose cancer recurs or spreads. This means that new therapeutic approaches are urgently needed for these patients.
"Gene therapy could be highly promising for the treatment of prostate cancer, but its use is currently limited by the lack of delivery systems which can selectively deliver the therapeutic genes to the tumors without adverse side effects for healthy tissues.
"To address this, we develop a new 'seek-and-destroy' nanomedicine linked to an iron-carrying protein called lactoferrin, whose receptors are found in large amounts in many cancers. The results show that it is highly promising for the treatment of prostate cancer by gene therapy."
The research was carried out on two prostate cancer cell lines, PC-3 and DU145, in laboratory settings.
The intravenous administration of the nanomedicine treatment resulted in the complete disappearance of 70% of the PC-3 tumors and half of the DU145 prostate tumors over one month.
The research was funded by Worldwide Cancer Research - formerly known as AICR.
Dr Matthew Lam, Science Communications Manager at Worldwide Cancer Research said: "We are delighted to see that this research is making the advances that could one day see gene therapy used to treat prostate cancer patients in the clinic. The clever chemistry employed in this study to enable the delivery of the treatment right at the heart of the tumor is a promising step forward.
"Our thanks goes to the brilliant supporters of Worldwide Cancer Research, whose generous donations have made this research possible."